Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Two-year results of phaco-canaloplasty in patients with concomitant advanced pseudoexfoliation glaucoma and cataract

Poster Details

First Author: J.Hasanov AZERBAIJAN

Co Author(s):                        

Abstract Details

Purpose:

To assess the safety and efficacy of phaco-canaloplasty in patients with concomitant advanced pseudoexfoliation (PXF) glaucoma and cataract.

Setting:

Prospective study

Methods:

Fifty six eyes of fifty five patients with concomitant advanced PXF glaucoma and cataract underwent phaco-canaloplasty surgery at Zarifa Aliyeva National Eye Centre (ZANEC). Canaloplasty was performed with a 10-0 polypropylene tensioning suture guided by Glaucolight microcatheter. All patients were followed for 24 months. Visual acuity, changes of intraocular pressure (IOP), use of glaucoma medications, incidence of complications and postsurgical interventions were examined.

Results:

Mean preoperative IOP decreased significantly from 29.7 mmHg (61.6-15.8) with a mean of 2.6 (4-0) glaucoma medications to 12.9 mmHg (19.6-5) with a mean of 0.17 (3-0) respectively in 24 months. Mean preoperative visual acuity increased from 0.1 (0.01-0.5) to 0.5 (0.01-1.2) by the final examination. The most frequent postoperative complications included mild hyphema (37 eyes), which disappeared within 7-14 days; descemet membrane perforation (4 eyes); IOP spikes (4 eyes); and inflammation (4 eyes). Descemeto-gonio puncture was performed (4 eyes).

Conclusions:

Phaco-canaloplasty is an exciting procedure that aims to re-establish the natural outflow system and led to a significant IOP reduction, had short term postoperative safety profile in patients with concomitant advanced PXF glaucoma and cataract.

Financial Disclosure:

NONE

Back to Poster listing